Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

RegulatoryapprovedXTX501Positive

AI Analysis

Summary

Xilio Therapeutics announced Q2 2026 financial results and received FDA clearance for the IND application of XTX501, a bispecific PD-1/masked IL-2 therapeutic candidate.

Clinical Trial Data

Phase

Phase_1

Outcome Details

FDA clearance of IND application

Importance:6/10

Sentiment:

0.70

IND clearancebispecificPD-1IL-2Q2 2026 results

Read the original article

Published by GlobeNewswire Pharma on August 12, 2026 11:30 AM

Read Original